anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a method for preparing aftosa vaccines, which comprises the technologies of cell culture, virus propagation and vaccine preparation. Germ viruses and a viral culture liquid are inoculated in monolayer cells after the monolayer cells grow to the full, wherein the dosage of the germ viruses accounts for 1 to 5% of the viral culture liquid, the viral culture liquid mainly comprises 85 to 90% of Edamin K solution, 0.5 to 2% of antibiotic, 5 to 10% of amino acid solution, 3% of 1% glutamine solution and 0.5 to 0.8% of HEPES, and the pH of the viral culture liquid can be regulated to 7.5(+/-)0.1 by adding aqueous alkali. The germ viruses and the viral culture liquid are mixed to prepare the aftosa vaccines after the viruses are inactivated, the proportion of divalent vaccine antigens is 1 to (1 to 3), and the proportion of trivalent vaccine antigens is 1 to (1 to 3) to (1 to 3). When two-phase adjuvant vaccines are prepared, the adjuvant is French SEPPIC ISA206, and the ratio of the adjuvant to the mixed antigens is 1 to 1. When single-phase adjuvant vaccines are prepared, the adjuvant is French SEPPIC 50V, and the ratio of the adjuvant to the mixed antigen is 1 to 1. The present invention is convenient for ultra large scale preparation, is suitable to prepare polyvalent vaccines, has no limitation to the use of strains, reduces the doses of the strains, and simultaneously guarantees immune efficacy.
The present invention provides a method for the covalent immobilization of biomolecules on polymers for delivery of the biomolecules, which has the advantage of being simple, highly efficient, environmentally friendly and free of side products relative to traditional immobilization techniques. The invention provides a modified micro/nanoparticle system, which uses a functionalized polymer formed into micro or nanoparticles to bind a molecule to the particles using uses facile chemistry, the Diels-Alder cycloadditon between a diene and a dienophile with the polymer being functionalized with one of them and the molecule with the other, or the Huisgen 1,3-dipolar cycloaddition between a terminal alkyne and an azide to bind the molecule to the particle. The molecules and/or other therapeutic agents may be encapsulated within the polymer particles for intravenous therapeutic delivery. The invention also provides a novel synthetic biodegradable polymer, a furan/alkyne-functionalized poly(trimethylene carbonate) (PTMC)-based polymer, whose composition can be designed to meet the defined physical and chemical property requirements. In one example, the particle system self-aggregates from functionalized PTMC-based copolymers containing poly(ethylene glycol) (PEG) segments. The composition of the copolymers can be designed to meet various particle system requirements, including size, thermodynamic stability, surface PEG density, drug encapsulation capacity and biomolecule immobilization capacity.
UNLABELLED: Enterovesical fistula represents an abnormal communication between the intestine and bladder. The causes are diverticulitis (56.3%), malignant tumours, which are located mainly in the intestine (20.1%), and Crohn's disease (9.1%). Other causes include iatrogenic injury (3.2%); trauma; foreign bodies in the intestinal tract; radiotherapy; chronic appendicitis; tuberculosis; and syphilis. Normal vaginal delivery as a cause for enterovesical fistula has not been reported in many publications yet. We report a case of a 30-year-old female, who developed an jejunovesical fistula after normal vaginal delivery. It was diagnosed after diagnostic cystoscopy and computed tomography of the abdomen and pelvis. There was jejuno-vesical fistula. Resection of the segment of the jejunum with side-to-side anastomosis with bladder repair was done. A follow-up cystogram was done which showed no contrast extravasation into the peritoneum. The patient was followed up for 9 months after surgery.
KEYWORDS: case reports; fistula; jejunum; urinary bladder.
Cognitive training was carried out by three trained and certified nurses in accordance with the cognitive training program. Twice a day, 30min each time, for 4 weeks, the difficulty of the training content is divided into 2 levels, the correct rate of more than 80% can enter the next level. During hospitalization, the patients and their families were taught how to use cognitive training programs. After discharge, special personnel were assigned to supervise and urge the patients to carry out cognitive training through the background.
Welchol (colesevelam hydrochloride) is a bile acid sequestrant (BAS) recently approved by the FDA for glucose lowering in patients with type 2 diabetes mellitus. Four randomized, controlled clinical studies in subjects with type 2 diabetes have demonstrated significant treatment difference in HbA1c (-0.5%). Study durations ranged from 12-26 weeks of therapy. In diabetes clinical studies, a therapeutic response to colesevelam hydrochloride, as reflected by reduction in A1c was initially noted following 4-6 weeks of treatment and reached maximal or near-maximal effect after 12-18 weeks of treatment. Reductions in both fasting plasma glucose and postprandial concentrations have been demonstrated. Simple measures of insulin secretion and action have suggested that this is due to improved insulin action rather than improved insulin secretion. The mechanism by which bile acids interact with the key pathways regulating glucose concentrations is largely unknown. The investigators propose a randomized, double-blind, placebo controlled trial with a parallel-group design where subjects are randomized to receive colesevelam or matching placebo for a 12 week treatment period. A labeled mixed meal before and after treatment will be used to measure intestinal transit, postprandial and fasting glucose fluxes, insulin secretion and action as well as enteroendocrine secretion.
INTRODUCTION: Childhood obesity is increasing worldwide and presents as a global health issue due to multiple metabolic comorbidities. About 1% of adolescents with obesity develop type 2 diabetes (T2D); however, little is known about the genetic and pathophysiological background at young age. The objective of this study was to assess the prevalence of impaired glucose regulation (IGR) in a large cohort of children and adolescents with obesity and to characterize insulin sensitivity and insulin secretion. We also wanted to investigate adolescents with insulin secretion disorder more closely and analyze possible candidate genes of diabetes in a subcohort.
METHODS: We included children and adolescents with obesity who completed an oral glucose tolerance test (OGTT, glucose + insulin) in the outpatient clinic. We calculated Matsuda index, the area under the curve (AUC (Ins/Glu)), and an oral disposition index (ISSI-2) to estimate insulin resistance and beta-cell function. We identified patients with IGR and low insulin secretion (maximum insulin during OGTT < 200 mU/l) and tested a subgroup using next generation sequencing to identify possible mutations in 103 candidate genes.
RESULTS: The total group consisted of 903 children and adolescents with obesity. 4.5% showed impaired fasting glucose, 9.4% impaired glucose tolerance, and 1.2% T2D. Matsuda index and Total AUC (Ins/Glu) showed a hyperbolic relationship. Out of 39 patients with low insulin secretion, we performed genetic testing on 12 patients. We found five monogenetic defects (ABCC8 (n = 3), GCK (n = 1), and GLI2/PTF1A (n = 1)).
CONCLUSION: Using surrogate parameters of beta-cell function and insulin resistance can help identify patients with insulin secretion disorder. A prevalence of 40% mutations of known diabetes genes in the subgroup with low insulin secretion suggests that at least 1.7% of patients with adolescent obesity have monogenic diabetes. A successful molecular genetic diagnosis can help to improve individual therapy.
PURPOSE:To obtain frozen microcapsules useful as a targeting or sustained release material in vivo in the drug delivery system, preservable for a long period of time, usable on merely melting, by introducing a glycolipid into microcapsules followed by freezing. CONSTITUTION:A glycolipid is introduced into phospholipid microcapsules and a functional substance is included in them or held in microcapsule bimolecular films and then frozen rapidly to obtain the objective frozen microcapsules. The microcapsules thus obtained cause little change in their diameter or leakage of the contents even after long-term storage at -5 deg.C, therefore being highly stable. The glycolipid is pref. an oligoglycolipid where hydrophobic groups have been bound to an oligosaccharide made up of an integer of 4-30 saccharide units. The binding mode is pref. ester linkage, ether linkage or amide linkage. The hydrophobic group is e.g. 12-22C alkyl chain, esp. cholesterol, glyceroskeleton. The frozen microcapsules are of much utility value such as utilization to hemoglobin solution-included artificial oxygen carriers.
Population Ⅴ has 20 subjects aged 3 to 5 and is considered negative for SARS-COV-2 and fluorescent RT-PCR nucleic acids. PopulationⅤ is intramuscular injection of deltoid muscle of upper arm with vaccine.
Provided are methods for treating or preventing Parkinson's disease or dementia with Lewy Bodies in a human subject. The methods target lipid dysregulation in brain tissue of the subject and can, in particular, reduce the concentration of glycosphingolipids in brain tissue. The methods use quinuclidine compounds of formula (I), or pharmaceutically acceptable prodrugs or salts thereof. In particular, the human subject may be a carrier of one or more glucocerebrosidase 1 gene (GBA1) mutations, e.g. a heterozygous carrier of GBA1 mutations. Also provided are methods for assessing the effectiveness of treatments as described herein.
Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
After receiving two 4-week cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) induction therapy, SER participants in Group 1 will receive pembrolizumab 2 mg/kg up to a maximum of 200 mg (3 to 17 years of age) or 200 mg (18 to 25 years of age) on Day 1 of each 3-week cycle (Q3W) in combination with two cycles of AVD chemotherapy (doxorubicin 25 mg/m\^2, vinblastine 6 mg/m\^2 and dacarbazine 375 mg/m\^2 on Days 1 and 15; cycle frequency every 4 weeks \[Q4W\]). All SERs in Group 1 will receive radiotherapy (RT) after completing AVD chemotherapy.
Blue light has been shown to release bioactive nitric oxide (NO) from nitrite and nitrosated proteins found in high concentrations in the skin. This bioactive NO has many physiological functions regulating immune responses, proliferation / differentiation as well as local blood Perfusion of the skin. The study will test the PSO-CT02 device, an new investigational medical device emitting blue light with a peak wavelength of 453nm on treating localised mild Psoriasis vulgaris. It can be worn on the Skin above the effected skin area. In this study Treatment (target) and control area as well as intensity of blue light are randomized. The control area will serve as reference. 50 Patients will treat the target area daily (at least 5 times/week) at home for an initial treatment period of 4 weeks. During those 4 weeks, patients will return to the study site for safety and effectiveness assessments twice. After this initiation period patients will treat their plaque for further 8 weeks (3 times/week). This is followed by a 4 week follow up phase without treatment.
Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.
The renal angina index (RAI) is a validated scoring tool for predicting acute kidney injury (AKI). We investigated the efficacy of the RAI in 2436 heterogeneous patients (mean age, 70 years) treated in cardiac intensive care units (CICUs). The RAI was calculated from creatinine and patient condition scores. AKI was diagnosed by the Kidney Disease: Improving Global Outcome criteria. The primary and secondary endpoints were the development of severe AKI and all-cause mortality, respectively. Four hundred thirty-three patients developed AKI, 87 of them severe. In multivariate analyses, the RAI was a significant independent predictor of severe AKI. During the 12-month follow-up period, 210 patients suffered all-cause death. Elevated RAI was independently associated with all-cause mortality, as was NT-proBNP (p < 0.001). The RAI is a potent predictor not only of severe AKI but also of adverse outcomes and substantially improved the 12-month risk stratification of patients hospitalized in CICUs.
Only a few cases of human overdose with amlodipine have been reported. One patient was asymptomatic after a 250 mg ingestion; another, who combined 70 mg of amlodipine with an unknown large quantity of a benzodiazepine, developed refractory shock and died.

Human overdoses with any combination of amlodipine and benazepril have not been reported. In scattered reports of human overdoses with benazepril and other ACE inhibitors, there are no reports of death. 

Treatment: Patients should be admitted to hospital and, generally, should be managed in an intensive care setting, with continuous monitoring of cardiac function, blood gases, and blood biochemistry. Emergency supportive measures such as artificial ventilation or cardiac pacing should be instituted if appropriate. 

In the event of a potentially life-threatening oral overdose, use induction of vomiting or gastric lavage and/or activated charcoal to remove the drug from the gastrointestinal tract (only if presented within 1 hour after ingestion of amlodipine and benazepril hydrochloride). 

Other clinical manifestations of overdose should be managed symptomatically based on modern methods of intensive care. 

To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison-Control Center. Telephone numbers of certified poison-control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdose, consider the possibilities of multiple-drug overdoses, drug-drug interactions, and unusual drug kinetics in your patient. 

The most likely effect of overdose with amlodipine and benazepril hydrochloride is vasodilation, with consequent hypotension and tachycardia. Simple repletion of central fluid volume (Trendelenburg positioning, infusion of crystalloids) may be sufficient therapy, but pressor agents (norepinephrine or high-dose dopamine) may be required. With abrupt return of peripheral vascular tone, overdoses of other dihydropyridine calcium channel blockers have sometimes progressed to pulmonary edema, and patients must be monitored for this complication. 

Analyses of bodily fluids for concentrations of amlodipine, benazepril, or their metabolites are not widely available. Such analyses are, in any event, not known to be of value in therapy or prognosis. 

No data are available to suggest physiologic maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of amlodipine, benazepril, or their metabolites. Benazeprilat is only slightly dialyzable; attempted clearance of amlodipine by hemodialysis or hemo-perfusion has not been reported, but amlodipine’s high protein binding makes it unlikely that these interventions will be of value. 

Angiotensin II could presumably serve as a specific antagonist-antidote to benazepril, but angiotensin II is essentially unavailable outside of scattered research laboratories.
Parkinson's disease is a chronic progressive neurodegenerative disease with highly heterogeneous symptoms and progression. It is helpful for patient management to establish a personalized model that integrates heterogeneous interpretation methods to predict disease progression. In the study, we propose a novel approach based on a multi-task learning framework to divide Parkinson's disease progression modeling into an unsupervised clustering task and a disease progression prediction task. On the one hand, the method can cluster patients with different progression trajectories and discover new progression patterns of Parkinson's disease. On the other hand, the discovery of new progression patterns helps to predict the future progression of Parkinson's disease markers more accurately through parameter sharing among multiple tasks. We discovered three different Parkinson's disease progression patterns and achieved better prediction performance (MAE=5.015, RMSE=7.284, r2=0.727) than previously proposed methods on Parkinson's Progression Markers Initiative datasets, which is a longitudinal cohort study with newly diagnosed Parkinson's disease.
This group will receive 12 hours double phototherapy in cycles of 1,5 hours. Thus receiving 1,5 hours treatment, 1,5 hours pause, 1,5 hours treatment etc.
A unified imaging platform is disclosed. The unified imaging platform can be adapted for use with a variety of medical imaging devices. The unified medical imaging platform can include a display, a processor, a data storage device and one or more external interfaces. The unified imaging platform can be removably coupled to a medical imaging device such as an endoscope. The unified imaging platform can be coupled to the medical imaging device via a wired or wireless link. Using web services, the unified imaging platform can also transfer image data to other devices including a local desktop computer system, a mobile device and/or a remote system.
Prior studies associated with a patient are pre-fetched from multiple institutions and made available to a radiologist while the radiologist is viewing a series. Intelligent report generation is template driven with templates based on modality, body part, and radiologist. The template provides access to macros specific to the study as well as previously dictated entries for particular fields, to enable re-use of standard text in a contextual manner. Likewise, entry of text in one field of the report may cause related text to be propagated to other fields, such as from the findings to the impression, automatically as specified by the radiologist. Billing codes are automatically applied based on the report content. Communication by the radiologist with other physicians and institutions is implemented via the reporting system. Since communication instances pass through the radiology system, it is possible to associate and log communication instances with the studies.
The invention discloses a pure traditional Chinese medicine for treating hypertension and belongs to the technical field of traditional Chinese medicines. The medicine does not contain western medicine ingredients and is prepared from pure natural raw materials including plants, animals and minerals which are ground to be fine powder and mixed. Hypertension belongs to arteriosclerosis, the amount of blood supplied to visceral organs is reduced, work load is heavier, and the visceral organs have lesion. Patients suffering from hypertension mainly have the symptoms of headache, dizziness, tinnitus, giddiness, amnesia, insomnia, anxiety, palpitate, weakness and the like; physiological and pathological characteristics are as follows: the liver governs ascending and motions and is the strong visceral organ, liver qi and liver yang are usually surplus and liver blood and liver yin are usually insufficient. The liver has lesion but the root is the kidney. Currently, a great variety of medicines for treating hypertension exist, and the medicine is a pure traditional Chinese medicine preparation and provides a treatment method.
The present invention relates to the technical field of medical treatment health products, particularly to a method for preparing garlic oil pills. The method disclosed by the present invention uses refined safflower oil or liquid paraffin for extracting for 24 to 72 hours in the temperature from 10 to 40 DEG C. Natural activity of all effective ingredients in garlic is reserved, and the extraction rate and the contents of volatile oil are also high. The present invention also comprises 21 types of trace elements and multiplex vitamin except for the volatile oil. Compared with the steam distillation method, the clinical action range of single ingredient is wide. Compared with the method that corn oil and sunflower oil are used as extracting agents for extracting the volatile oil, the volatile oil extracted by the present invention has high contents, low cost and good external appearance color. The present invention is suitable for industrial production.
A total of 16 subjects were randomly assigned to each dose group for multiple dose study , including 12 who received FCN-207 tablets and 4 who received placebo for a 10-day administration cycle. The dosage of multiple administration was based on the results of single ascending dose study results , and the method of drug administration refers to the results of the food influence test.
PURPOSE:To obtain a cosmetic material excellent in emulsifiability and humectant effect and highly safe to the skin. CONSTITUTION:This cosmetic material is obtained by decomposing conchiolin or a hydrolyzate thereof in a weakly alkaline state with an oxidizing agent (pref. hydrogen peroxide, peracetic acid or performic acid). Use of an emulsifier as a decomposing agent facilitates the regulation of the molecular weight of the product after decomposition. Besides, after decomposition by an oxidizing agent, further decomposition by a protease is effective for regulating the molecular weight of the final product. When the cosmetic material obtained by these treatments is further treated with succinic anhydride at pH 6-9, the humectancy as well as the emulsifiability of this cosmetic material is improved.
PURPOSE: A composition containing nicotinamide is provided to protect anticancer drug-inducible neurotoxicity. CONSTITUTION: A composition for preventing or treating alkylation drug-inducible neurodegeneration contains nicotinamide as an active ingredient. The alkylation drug includes melpalan, cyclophosphamide, chlorambucil, dihydroxy busulfan, or thiotepa. The composition additionally contains a pharmaceutically acceptable carrier. The concentration of nicotinamide is 0.1mg-5mg per body weight(g). A health food for preventing or treating alkylation drug-inducible neurodegeneration contains nicotinamide as an active ingredient.
Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. An increased plasma concentration of pimozide causes QT prolongation and has been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal. As noted below, a substantial pharmacokinetic interaction has been observed for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by CYP3A4. Although it has not been definitively demonstrated that fluvoxamine is a potent CYP3A4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam. Consequently, it is recommended that fluvoxamine not be used in combination with pimozide. [See CONTRAINDICATIONS (4.1)].